Form 4: Director Paul Stuka Increases Stake in InspireMD

Director Paul Stuka acquired 15,000 shares of InspireMD, Inc. common stock through open market purchases.

Summary

• Director Paul Stuka purchased 10,000 shares of common stock on May 13, 2026, at a weighted average price of $1.1575.
• Director Paul Stuka purchased an additional 5,000 shares of common stock on May 14, 2026, at a price of $1.15.
• Following these transactions, the director's direct beneficial ownership increased to 647,871 shares.
• The director maintains an indirect interest in 423,704 shares held by Osiris Investment Partners, L.P.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as director-level insider buying typically reflects confidence in the company's future prospects.

Positives

• Insider confidence is demonstrated by the director's decision to increase his equity position in the company.
• Purchases were made via open market transactions, signaling alignment with shareholder interests.

Negatives

• None identified.

Risks

• Market volatility affecting the value of the acquired shares.
• General risks associated with the medical device industry and regulatory environment.

Future Outlook

Not applicable as this is an insider transaction report.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal of management's belief in the company's long-term valuation and strategic direction within the medical device sector.

Comparison to Industry Standards

• Insider buying is a standard practice among board members to signal commitment to company growth.
• The volume of shares purchased is consistent with typical director-level equity accumulation.

Related Party Transactions

• The reporting person is the managing member of Osiris Partners, LLC, which is the general partner of Osiris Investment Partners, L.P., a holder of 423,704 shares.

Stakeholder Impact

• Shareholders may interpret the director's purchase as a vote of confidence in the company's current valuation.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Recommendation

While insider buying is a positive indicator, a single Form 4 filing does not provide sufficient fundamental data to warrant a buy or sell rating on its own.

Keywords

InspireMD, NSPR, Insider Trading, Form 4, Director Purchase, Equity Ownership